United Therapeutics Q2 2022 revenue up 5% to $466.9M; net income down 33%

UNITED THERAPEUTICS Corp

2022-Q2 EPS reported $7.43 revenue$928,800,000

Total revenues $466.9M (+5% YoY); net income $116.0M ($2.41 diluted EPS) vs $172.6M ($3.65) in Q2 2021.
Tyvaso sales $201.0M (+31%) from PH-ILD label expansion; ~500 additional Tyvaso patients in Q2.
Share-based compensation $65.5M (+125%), driven by STAP expense from 31% stock price increase.
FDA approved Tyvaso DPI in May 2022 for PAH and PH-ILD; commercial shipments began in June.
CMS updated Tyvaso coverage for PH-ILD effective June 5, 2022, supporting further patient growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.